Suppr超能文献

1999-2012 年韩国新诊断抗逆转录病毒治疗初治 HIV/AIDS 患者传播耐药趋势。

The trend of transmitted drug resistance in newly diagnosed antiretroviral-naive HIV/AIDS patients during 1999-2012 in South Korea.

机构信息

Division of AIDS, Department of Immunology and Pathology, National Institute of Health South Korea, The Korea Centers for Disease Control and Prevention, Republic of Korea.

Division of AIDS, Department of Immunology and Pathology, National Institute of Health South Korea, The Korea Centers for Disease Control and Prevention, Republic of Korea.

出版信息

J Clin Virol. 2016 Aug;81:53-7. doi: 10.1016/j.jcv.2016.06.001. Epub 2016 Jun 2.

Abstract

BACKGROUND

The use of antiretroviral drugs has reduced the mortality and morbidity of patients with HIV/AIDS. More than 20 antiretroviral drugs have been used in patients with HIV/AIDS since zidovudine was first introduced in 1991 in South Korea.

OBJECTIVES

To investigate and estimate the annual prevalence of transmitted drug resistance and drug-resistant variants of HIV-1 in newly diagnosed antiretroviral-naive patients in South Korea during 1999-2012.

STUDY DESIGN

Plasma specimens were collected from 928 antiretroviral-naive patients during 1999-2012. Mutations in the protease and reverse transcriptase sections of the HIV-1 pol gene were identified using the Stanford HIV Drug Resistance Database (Stanford DB).

RESULTS

Among 928 HIV-1 isolates from antiretroviral-naive patients, 45 (4.8%) showed 'intermediate' or 'resistant' drug resistance. The predicted prevalence of drug resistance among isolates was 2.2%, 2.7%, and 0.3% for resistance to nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors, respectively.

CONCLUSIONS

There was no significant increase in the prevalence of drug resistance among antiretroviral-naive patients infected with HIV-1 during 1999-2012 in South Korea, although there was a slight increase during 2009-2012. The emergence of drug-resistant variants will continue to be monitored by national surveys.

摘要

背景

抗逆转录病毒药物的使用降低了 HIV/AIDS 患者的死亡率和发病率。自 1991 年韩国首次引入齐多夫定时,已有 20 多种抗逆转录病毒药物用于治疗 HIV/AIDS 患者。

目的

调查和估计 1999 年至 2012 年期间韩国新诊断的抗逆转录病毒初治患者中 HIV-1 传播耐药性和耐药变异体的年度流行率。

研究设计

1999 年至 2012 年期间,从 928 名抗逆转录病毒初治患者中采集了血浆标本。使用斯坦福 HIV 耐药性数据库(Stanford DB)鉴定 HIV-1 pol 基因的蛋白酶和逆转录酶部分的突变。

结果

在 928 名抗逆转录病毒初治患者的 HIV-1 分离株中,有 45 株(4.8%)显示出“中度”或“耐药”耐药性。预测对核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂的耐药性在分离株中的发生率分别为 2.2%、2.7%和 0.3%。

结论

尽管在 2009 年至 2012 年期间略有增加,但韩国 1999 年至 2012 年期间新感染 HIV-1 的抗逆转录病毒初治患者中耐药性的流行率没有显著增加。耐药变异体的出现将继续通过国家调查进行监测。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验